CN105246887B - 香豆素衍生物以及用于治疗过度增生性疾病的方法 - Google Patents

香豆素衍生物以及用于治疗过度增生性疾病的方法 Download PDF

Info

Publication number
CN105246887B
CN105246887B CN201480015013.4A CN201480015013A CN105246887B CN 105246887 B CN105246887 B CN 105246887B CN 201480015013 A CN201480015013 A CN 201480015013A CN 105246887 B CN105246887 B CN 105246887B
Authority
CN
China
Prior art keywords
compound
dbm
compounds
cells
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201480015013.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN105246887A (zh
Inventor
E.施维伯特
J.施特雷夫
J.迪克松
H.高
J.P.里基
E.C.西尔斯
D.麦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Discoverybiomed Inc
Original Assignee
Discoverybiomed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Discoverybiomed Inc filed Critical Discoverybiomed Inc
Publication of CN105246887A publication Critical patent/CN105246887A/zh
Application granted granted Critical
Publication of CN105246887B publication Critical patent/CN105246887B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201480015013.4A 2013-03-15 2014-03-14 香豆素衍生物以及用于治疗过度增生性疾病的方法 Expired - Fee Related CN105246887B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361788398P 2013-03-15 2013-03-15
US61/788398 2013-03-15
PCT/US2014/027154 WO2014152278A2 (en) 2013-03-15 2014-03-14 Coumarin derivatives and methods of use in treating hyperproliferative diseases

Publications (2)

Publication Number Publication Date
CN105246887A CN105246887A (zh) 2016-01-13
CN105246887B true CN105246887B (zh) 2018-05-11

Family

ID=51581693

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480015013.4A Expired - Fee Related CN105246887B (zh) 2013-03-15 2014-03-14 香豆素衍生物以及用于治疗过度增生性疾病的方法

Country Status (10)

Country Link
US (1) US10369145B2 (enExample)
EP (1) EP2970249A4 (enExample)
JP (1) JP6407955B2 (enExample)
KR (1) KR20150132483A (enExample)
CN (1) CN105246887B (enExample)
AU (1) AU2014240003B2 (enExample)
CA (1) CA2903107C (enExample)
HK (1) HK1218537A1 (enExample)
MX (1) MX379292B (enExample)
WO (1) WO2014152278A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2836463A1 (en) 2011-05-17 2012-11-22 Discoverybiomed Inc. Treating protein folding disorders with small molecule cftr correctors
AU2013348018A1 (en) 2012-11-20 2015-06-04 Discoverybiomed, Inc. Small molecule CFTR correctors
WO2014081821A2 (en) 2012-11-20 2014-05-30 Discoverybiomed, Inc. Small Molecule Bicyclic and Tricyclic CFTR Correctors
CA2903103C (en) 2013-03-15 2020-06-09 Discoverybiomed, Inc. Coumarin derivatives and methods of use in treating cystic fibrosis, chronic obstructive pulmonary disease, and misfolded protein disorders
CN105246887B (zh) 2013-03-15 2018-05-11 发现生物医药公司 香豆素衍生物以及用于治疗过度增生性疾病的方法
CN105541852B (zh) * 2016-01-29 2017-09-15 扬州大学 2‑（香豆素‑3‑基）‑6‑甲基吡啶并[5,4‑c]香豆素的合成方法
CN107098895B (zh) * 2016-02-19 2020-01-07 湖南大学 苯氨基噻唑甲基喹啉酮衍生物及其制备方法与应用
JP2020525446A (ja) * 2017-06-21 2020-08-27 ザ・ジョンズ・ホプキンス・ユニバーシティ 常染色体優性多発性嚢胞腎疾患を治療するための嚢胞性線維症膜貫通コンダクタンス制御因子の調節因子
CN109464440A (zh) * 2019-01-17 2019-03-15 北京大学 3-乙酰氨基香豆素在制备治疗或预防肾脏纤维化及慢性肾病的药物中的应用
CN112274517A (zh) * 2020-10-30 2021-01-29 江苏大学 一种治疗套细胞淋巴瘤的药物组合物
KR20250109620A (ko) * 2024-01-09 2025-07-17 주식회사 프로티나 신규 화합물 및 이의 용도

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003066630A2 (en) * 2002-02-07 2003-08-14 Amgen Inc. Quinolinone derivatives for treating cell proliferation related disorders
WO2003105842A1 (en) * 2002-06-13 2003-12-24 Novuspharma S.P.A. Derivatives of chromen-2-one as inhibitors of vegf production in mammalian cells
CN101351208A (zh) * 2005-11-01 2009-01-21 康乃尔研究基金会有限公司 减少细胞胆固醇水平和/或治疗或预防磷脂质病
WO2010111713A2 (en) * 2009-03-27 2010-09-30 Zacharon Pharmaceuticals, Inc. N-linked glycan biosynthesis modulators

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5566580A (en) * 1978-11-11 1980-05-20 Kaken Pharmaceut Co Ltd Coumarin derivative, its preparation and antiallergic agent containing the same as effective component
US20030055263A1 (en) 2001-07-11 2003-03-20 Boehringer Ingelheim Pharma Kg Carboxylic acid derivatives, medicaments comprising these compounds, their use and processes for their production
DE10133665A1 (de) 2001-07-11 2003-01-30 Boehringer Ingelheim Pharma Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Herstellung
KR20070084067A (ko) 2004-10-13 2007-08-24 와이어쓰 Ｎ-벤젠설포닐 치환 아닐리노-피리미딘 동족체
CN101076703A (zh) 2004-10-13 2007-11-21 Ptc医疗公司 用于无义抑制的化合物及其使用方法
WO2006044456A1 (en) * 2004-10-13 2006-04-27 Ptc Therapeutics, Inc. Compounds for nonsense suppression, and methods for their use
US20090012148A1 (en) * 2005-11-01 2009-01-08 Maxfield Frederick R Reducing cellular cholesterol levels and/or treating or preventing phospholipidosis
EP2581451B1 (en) 2007-12-13 2016-03-09 Indiana University Research and Technology Corporation Compounds for inhibiting mammalian s-nitrosoglutathione reductase
ITMI20111068A1 (it) 2011-06-14 2012-12-15 Azienda Ospedaliera Universitaria I Ntegrata Di Ve Trimetilangelicina come correttore di cftr in cellule dell'epitelio bronchiale
CN105246887B (zh) 2013-03-15 2018-05-11 发现生物医药公司 香豆素衍生物以及用于治疗过度增生性疾病的方法
CA2903103C (en) * 2013-03-15 2020-06-09 Discoverybiomed, Inc. Coumarin derivatives and methods of use in treating cystic fibrosis, chronic obstructive pulmonary disease, and misfolded protein disorders

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003066630A2 (en) * 2002-02-07 2003-08-14 Amgen Inc. Quinolinone derivatives for treating cell proliferation related disorders
WO2003105842A1 (en) * 2002-06-13 2003-12-24 Novuspharma S.P.A. Derivatives of chromen-2-one as inhibitors of vegf production in mammalian cells
CN101351208A (zh) * 2005-11-01 2009-01-21 康乃尔研究基金会有限公司 减少细胞胆固醇水平和/或治疗或预防磷脂质病
WO2010111713A2 (en) * 2009-03-27 2010-09-30 Zacharon Pharmaceuticals, Inc. N-linked glycan biosynthesis modulators

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
A Convenient, Rapid and Eco-Friendly Synthesis of Isoxazoline Heterocyclic Moiety Containing Bridge at 2。-Amine as Potential Pharmacological Agent;J.T. Desai et al.;《J. Iran. Chem. Soc.》;20080331;第5卷(第1期);第67-73页 *
Double Functional Group Transformations for Fluorescent Probe Construction:A Fluorescence Turn-On Probe for Thioureas;Weiying Lin et al.;《Chem. Eur. J.》;20100519;第16卷;第6454-6457页 *
Double Functional Group Transformations for Fluorescent Probe Construction:A Fluorescence Turn-On Probe for Thioureas;Weiying Lin et al.;《India Chem. Soc.》;19711231;第48卷(第7期);第6454-6457页 *
STN;STN;《STN》;20161215 *
Synthesis and Evaluation of Some Substituted 2-Arylamino Coumarinyl Thiazoles as Potential NSAIDs;K.N.Venugopala et al.;《Asian Journal of Chemistry》;20041231;第16卷(第2期);第872-876页 *

Also Published As

Publication number Publication date
MX2015013175A (es) 2016-04-04
JP6407955B2 (ja) 2018-10-17
WO2014152278A3 (en) 2014-11-13
HK1218537A1 (zh) 2017-02-24
US10369145B2 (en) 2019-08-06
US20160038475A1 (en) 2016-02-11
EP2970249A4 (en) 2017-03-15
MX379292B (es) 2025-03-11
EP2970249A2 (en) 2016-01-20
CA2903107C (en) 2021-11-02
CA2903107A1 (en) 2014-09-25
WO2014152278A2 (en) 2014-09-25
AU2014240003B2 (en) 2017-12-14
CN105246887A (zh) 2016-01-13
JP2016513685A (ja) 2016-05-16
AU2014240003A1 (en) 2015-09-03
KR20150132483A (ko) 2015-11-25

Similar Documents

Publication Publication Date Title
CN105246887B (zh) 香豆素衍生物以及用于治疗过度增生性疾病的方法
CN109152933B (zh) 诱导抗细胞凋亡bcl-2家族蛋白的降解的化合物及其用途
CN103974948B (zh) 在治疗过度增殖性疾病中用作bub1激酶抑制剂的取代的苄基吲唑
CN104411701B (zh) 作为Bub1抑制剂的用于治疗癌症的取代的环烯并吡唑
JP6885999B2 (ja) 水溶性プロドラッグ
JP7539545B2 (ja) 複素環化合物及びその使用
JP2021512059A (ja) ブルトン型チロシンキナーゼ（ｂｔｋ）阻害剤のｅ３リガーゼリガンドとのコンジュゲーションによるｂｔｋの分解および使用方法
CN110267945A (zh) 氰基取代的吲哚化合物及其作为lsd1抑制剂的用途
TW200908983A (en) Heterocyclic compounds and uses thereof
WO2019015559A1 (zh) 作为ask抑制剂的杂环化合物及其应用
TW201625620A (zh) 作為蛋白去乙醯酶抑制劑及雙蛋白去乙醯酶蛋白激酶抑制劑之雜環氧肟酸及其使用方法
CN105517549B (zh) CaMKII抑制剂和其用途
CN110128415A (zh) 用作免疫调节剂的吲哚啉类化合物及其制备方法
WO2013013614A1 (zh) 4-(3-杂芳基芳基氨基)喹唑啉和1-(3-杂芳基芳基氨基)异喹啉作为Hedgehog通路抑制剂及其应用
CN103097367A (zh) 苯丙酸化合物、其制备方法及其医药用途
WO2017148406A1 (zh) 嘧啶类七元环化合物、其制备方法、药用组合物及其应用
CN107074856A (zh) CaMKII抑制剂及其用途
WO2017083756A1 (en) Heterocyclic compounds for the treatment of disease
CN110753691A (zh) 化合物
EP3388419A1 (en) Gli1 inhibitors and uses thereof
CN114957219B (zh) 一种靶向降解Gli1蛋白的降解剂及其制备方法和应用
CN107459491A (zh) 含1,2,3‑三氮唑结构的苯甲酰胺类化合物及其用途
US20170007610A1 (en) Novel heterobicyclic compounds as kappa opioid agonists
CN111777626A (zh) 一类维奈妥拉与二氢青蒿素拼合物及其制备与应用
KR20200011990A (ko) 단백질 키나제 저해제로서 유용한 피리도퀴나졸린 유도체

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20180511

CF01 Termination of patent right due to non-payment of annual fee